Member Info for D-Geeman

"Time waits for no one in the stock exchange, but I just can't stand hypocrites" says hahahehehoho, who complained about RMS people posting on the BRH board when they weren't invested there!
Takes all sorts..

Just out of interest are you guys also investing directly into Incanthera? New here myself. No access directly to Incanthera chat.

1509. Thanks for all your updates on RMS. I only hold a small amount (will keep whatever happens as I'd buy the mask myself; and then there are the other RMS branches) but I know you have faith and it's reassuring.

'The Lord Giveth (synairgen) And the Lord Taketh Away (RMS)'
This is the word of the Bulletin Board.

Press release
Synairgen plc
('Synairgen' or the 'Company')

COVID-19 Clinical Programme Update

- SNG001 given Fast Track designation and IND cleared by the US FDA
- Phase III trial design adapted which will expedite results
- Phase III trial to commence dosing in UK imminently

Southampton, UK - 18 December 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces updates to the Company's Phase III trial design evaluating SNG001 as a treatment for patients with COVID-19 and positive progress on the regulatory path.

Update to Phase III trial (SG018) protocol in COVID-19 patients
Following discussions with the regulatory agencies, the trial has been amended as follows:

· Removal of the lower dose arm, thereby reducing the number of patients required to complete the placebo-controlled trial from 900 patients to 610 patients
· Addition of a second primary endpoint. The primary endpoints are now 'time to hospital discharge' and 'time to recovery'. The primary assessment of efficacy will be supported by the key secondary endpoint of 'progression to severe disease or death' and other secondary endpoints. Both primary endpoints have at least 90% power to detect a statistically significant effect of SNG001 compared to placebo
· Addition of assessments for Long COVID-19 symptoms on day 60 and day 90

Initiation of the first SG018 sites has commenced in the UK, with dosing expected to commence imminently. The SG018 trial was deemed an Urgent Public Health study and recognised as a National Priority by the National Institute for Health Research (NIHR) in October 2020.

Investigational New Drug clearance and Expedited Regulatory Pathway granted from the FDA
Synairgen's Investigational New Drug (IND) application to the FDA to evaluate SNG001 as a treatment for patients with COVID-19, has been cleared, enabling Synairgen to initiate its SG018 trial in the US. Furthermore, the FDA has awarded SNG001 Fast Track status, enhancing the ability of Synairgen to interact with the FDA and shortening review timelines.

Update on the SG016 home trial in COVID-19 patients
This trial targets patients with a positive SARS-CoV-2 test result who are aged over 65 and those over the age of 50 with 'high risk' medical conditions. It is a trial designed to make it easy and safe for trial participants and researchers to conduct the research; all supplies for the trial are delivered directly to the patient's door by courier, and all trial visits and assessments are conducted virtually by video call. After a slow start in the summer, recruitment and dosing are now progressing well with a noticeable increase in the last two months. Those interested in participating in the trial can visit www.covidtrialathome.com.

Richard Marsden, CEO of Synairgen, said: "With this adaptation we should be able to reduce the time taken to complete the trial, which, together with an expedited rev

Handy duvet promo in The Telegraph, and refers to Eve’s advertising

https://www.google.co.uk/amp/s/www.telegraph.co.uk/interiors/home/best-duvet-covers-bedding-sets-stylish-bedroom-update/amp/

If you have ever taken the Tube in London, you’ve probably seen an advert for Eve Sleep, with their distinctive yellow and white designs. But it seems their cotton duvet sets are just as eye-catching as their adverts, with their relaxed pastel pink design our personal favourite. The sheets are made from crisp cotton but are treated with a special enzyme wash to give it a soft linen-y look that just gets better the more creases it has, so you can ditch the ironing completely.

(...because it is somewhat complex.)The test kit comes with four different parts: a sterile nasal swab, a dropper, processing fluid and a small Bluetooth-connected device that analyzes your sample and syncs with a corresponding smartphone app. A video on the app shows you how to properly take the test, because it is somewhat complex.
To use the test, you first have to turn on the analyzer and pair it with your smartphone

All good. No panic

Migsmc186; " I'll wear a mask while watching TV at home or fornicating with the missus. Pure garbage as usual from Sadiq".
Sorry to be a pedant but you cannot fornicate with your own Missus: 'Fornication; Sexual intercourse between people not married to each other'.
So, if you are fornicating – by definition with someone else's Missus – then I strongly recommend you wear an anti-viral mask from RMS :-)

Donotpanic, Unless I'm misreading your post I wouldn't expect approval on Monday (tomorrow). Remember this from last RNS. Look at the asterix after 'certification':
'Volz has recently sent a batch of masks produced by them with P2F's anti-viral layer for certification*. Subject to successful certification of these masks the Company anticipates that its next step will be to place an order of 0.5m masks, incorporating P2F's anti-viral layer, for delivery to the UK in January 2021.
* certification is required for the production process and so separate certification processes are required for P2F's and Volz's production. Certification is now expected to be completed in the first week of January in both cases.

Scaredy, you should tweet that link to Lee Mack ('Lee Mack ‘utterly shocked’ at death of Not Going Out co-star Bobby Ball')

PL75. I'm quite a superstitious sort. I have a very strange feeling that if you write Avacta (not Awacta) in a post, not tonight but before Monday 7am, there'll be a positive RNS. And I'll get quite a few thumbs up..

https://www.expertreviews.co.uk/mattresses/1413019/dreamcloud-luxury-hybrid-mattress-review
'you’ll get a full year in which to test the DreamCloud Luxury Hybrid and decide if it's for you.
What’s more, DreamCloud also offers a lifetime warranty on its hybrid, which protects against defects in workmanship and materials, something no other bed-in-a-box manufacturer provides.'

I've heard that high percentage sofas and mattresses are produced domestically. Just tried to dig deeper (found a lot of industry reports that you have to pay for) and found a list of manufacturers of foam for mattresses. Eve must use these companies, or similar.
https://www.southernfoam.co.uk
https://www.google.com/search?client=safari&rls=en&q=mattress+foam+UK+manufacturer&ie=UTF-8&oe=UTF-8

Thanks Wyndrum. Sounds very sensible.. I myself am planning for 5 years anyway and my cash may as well be in Eve as anywhere else, if it's growing.
One thing that I've come to recognise more fully (now that things are so much better with sales) and you are / were right, at 1p Eve really was in a very perilous position. The move from 'bricks-and-mortar' to 'on-line' was definitely there (we bought an Eve Original ourselves and like it a lot) but I doubt Eve could have hung on, had the pandemic not accelerated the shift many times faster. It feels like a near-miss on the road, one you only appreciate after you've driven a mile or two.

Ocado came out with good figures (to me anyway) this morning, and yet sp is down 7% as I write: shareholders are pretty demanding. In my mind there's zero doubt regarding Eve's price rising towards Jan 21st but I wonder whether the rise will still be there on Jan 22nd, 23rd. Would a profit be enough to ensure it sticks do people think??

Being down 20% here I've left for a while to get the 20% – or more– back by Jan 21st / Jan 22nd. I will be back here around Jan 23rd though as i know this company has a great future (make sure not too much happens while I'm away pls..)
(anyone interested in where I put it can see where I post the most).
All the best. DG

Implies they've been virtually flat-out at times: “We could have sold more product, but we wouldn’t be able to deliver it with a great experience,” Calverley explains. “The damage that does to your brand is more than that revenue is worth.”

As part of Campaign's 'Not Normal' series of essays about 2020, we examine how bricks-and-mortar-based businesses have suffered, while ecommerce, social media and streaming services have hit the boom time as people have been forced to stay at home.
https://www.campaignlive.co.uk/article/review-2020-boom-time-digital-consumption/1702015
This atmosphere has forced brands to adapt. Cheryl Calverley, the ex-BMW and AA marketer, who was appointed chief executive of direct-to-consumer mattress brand Eve Sleep in April, admits the crisis has produced extreme emotions – bad and good.

“It’s horrendous. I’m not enjoying being locked to the corner of my room; I hate leading through a screen,” she says. “But I’ve also really enjoyed the marketing challenges that have come our way because they’ve been interesting and different. And relying on a team that is pulling together and being creative – I’ve never felt so proud.”

As non-essential retailers were forced to close, online demand for home delivery surged. But instead of simply trying to shift more mattresses, Eve has switched to offering a wider range of sleep-wellness products, as well as more content and online services to help people sleep better.
“We could have sold more product, but we wouldn’t be able to deliver it with a great experience,” Calverley explains. “The damage that does to your brand is more than that revenue is worth.”

1509. Really impressed with your German translation skills, of the Volz website (till I too pressed the union flag! ;-)